Latest Articles

Publication Date
Researchers use AI to speed up endometriosis diagnoses in Canada - CP24

Researchers use AI to speed up endometriosis diagnoses in Canada CP24

Published: April 12, 2026, 4:12 p.m.
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive

Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer OncLive

Published: April 12, 2026, 2:35 p.m.
Toronto researchers use AI to tackle endometriosis diagnostic delays - CTV News

Toronto researchers use AI to tackle endometriosis diagnostic delays CTV News

Published: April 12, 2026, 9 a.m.
Woman Gets Endometriosis Diagnosis After Years of ‘Debilitating’ Pain, Calls Treatment Options 'Barbaric’ - AOL.com

Woman Gets Endometriosis Diagnosis After Years of ‘Debilitating’ Pain, Calls Treatment Options 'Barbaric’ AOL.com

Published: April 12, 2026, 2:13 a.m.
Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer - OncLive

Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer OncLive

Published: April 12, 2026, 12:58 a.m.
Verzenio Plus Letrozole Shows Durable Responses in Advanced Endometrial Cancer - Cure Today

Verzenio Plus Letrozole Shows Durable Responses in Advanced Endometrial Cancer Cure Today

Published: April 11, 2026, 9:14 p.m.
Black Women With Endometrial Cancer Completed Treatment More With Peer Support - CancerNetwork

Black Women With Endometrial Cancer Completed Treatment More With Peer Support CancerNetwork

Published: April 11, 2026, 8:04 p.m.
Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer - OncLive

Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer OncLive

Published: April 11, 2026, 6:14 p.m.
Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma - OncLive

Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma OncLive

Published: April 11, 2026, 4:04 p.m.
BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer - Quiver Quantitative

BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer Quiver Quantitative

Published: April 11, 2026, 11:10 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!